FTC challenges Illumina’s purchase of cancer test manufacturer

Ben Remaly

31 March 2021

Illumina’s proposed $8 billion acquisition of Grail could give it sole control over the market for certain cancer-screening tests, the Federal Trade Commission has alleged in a lawsuit seeking to block the merger.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Editor, GCR USA

[email protected]

Tipline

Duking it out: The Tipline for 8 December 2023
Duke University might have thought its legal woes ended after settling with alumni claiming it was part of a financial aid cartel, but the battle is not over yet. The university has moved to the other side of the “v” and sued two of its insurance providers for refusing to cover the antitrust settlement. Also in Tipline, a former executive that worked in preventing soil erosion admits he rigged bids and the US Department …
Amateurism hour: The Tipline for 7 December 2023
In low Spirits: The Tipline for 6 December 2023

FTC challenges Illumina’s purchase of cancer test manufacturer

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Ben Remaly